Moving iPSC-Derived Cardiomyocytes Forward to Treat Myocardial Infarction

0Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Human pluripotent stem cell-derived cardiomyocytes represent a promising cell source for cardiac repair. However, their clinical translation is hindered by limited evidence for functional benefits in primate models, potential risks for arrhythmias, and teratoma formation. A recent study by Liu et al. (2018) makes significant progress on these critical issues. Human pluripotent stem cell-derived cardiomyocytes represent a promising cell source for cardiac repair. However, their clinical translation is hindered by limited evidence for functional benefits in primate models, potential risks for arrhythmias, and teratoma formation. A recent study by Liu et al. (2018) makes significant progress on these critical issues.

Cite

CITATION STYLE

APA

Tu, C., & Zoldan, J. (2018, September 6). Moving iPSC-Derived Cardiomyocytes Forward to Treat Myocardial Infarction. Cell Stem Cell. Cell Press. https://doi.org/10.1016/j.stem.2018.08.011

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free